Recent Advances in the Development of Mammalian Geranylgeranyl Diphosphate Synthase Inhibitors

Molecules. 2017 May 27;22(6):886. doi: 10.3390/molecules22060886.

Abstract

The enzyme geranylgeranyl diphosphate synthase (GGDPS) catalyzes the synthesis of the 20-carbon isoprenoid geranylgeranyl diphosphate (GGPP). GGPP is the isoprenoid donor for protein geranylgeranylation reactions catalyzed by the enzymes geranylgeranyl transferase (GGTase) I and II. Inhibitors of GGDPS result in diminution of protein geranylgeranylation through depletion of cellular GGPP levels, and there has been interest in GGDPS inhibitors as potential anti-cancer agents. Here we discuss recent advances in the development of GGDPS inhibitors, including insights gained by structure-function relationships, and review the preclinical data that support the continued development of this novel class of drugs.

Keywords: geranylgeranyl diphosphate synthase; geranylgeranylation; inhibitors; isoprenoid.

Publication types

  • Review

MeSH terms

  • Animals
  • Enzyme Inhibitors / chemistry*
  • Enzyme Inhibitors / pharmacology*
  • Farnesyltranstransferase / antagonists & inhibitors*
  • Farnesyltranstransferase / metabolism
  • Humans
  • Protein Prenylation / drug effects
  • Structure-Activity Relationship
  • Terpenes / chemistry
  • Terpenes / pharmacology

Substances

  • Enzyme Inhibitors
  • Terpenes
  • Farnesyltranstransferase